Medicinal Chemist Expert for Drug Discovery and Preclinical Development

Technical Consultant #2283


  • Medicinal Chemistry
  • Drug Discovery
  • Preclinical Development
  • Synthetic Organic Chemistry
  • Intellectual Property Strategies


Independent Consultant, 2004-Present

  • Provide independent R&D (medicinal chemistry, drug discovery and preclinical development), business development and fundraising consulting services for established and start-up biotech, pharma and diagnostic companies.

Vice President, Research & Development, Managing Director, Molecular Imaging, (Subsidiary of Siemens), 2003-2004

  • Device, Software, Radiotracer and Diagnostic R&D. Led integrated medicinal chemistry, radiochemistry, physics, biology, probe discovery and development, microfluidics, hardware and software engineering functions.
  • President and Director for subsidiary, CTI Technologies, Inc.
  • Initiated development on new PET radiotracers for imaging Alzheimer's disease and cancer; managed multiple device, software and probe projects.

President and Chief Scientific Officer, Ceretek, LLC, 2000-2003

  • Lead all R&D, Business Development and fundraising activities. Full P&L responsibilities.
  • Developed substantial intellectual property portfolio covering novel receptors, assays and lead compounds.
  • Established and implemented the Company strategy of drug discovery and development targeting Lipid G-Protein Coupled Receptors (L-GPCRs) to identify novel therapeutics for cancer, immune, cardiovascular, ophthalmic and CNS disorders.
  • Led team that identified first novel subtype selective Edg1, Edg2, Edg4 and Edg7 antagonists.

Vice President, Scientific Affairs, Questcor Pharmaceuticals, Inc., 1997-2000

  • Led Questcor'9s antiinfective and cytoprotective preclinical research. Line management responsibility for biology, chemistry, informatics, and screening for the company.
  • Developed novel and successful antibacterial, antifungal and antiviral (Hepatitis C) programs certain of which are currently in preclinical or early clinical development.

Director of Chemistry, Synaptic Pharmaceutical Corp., 1991-1997

  • Directed the chemistry effort for successful projects including: alpha 1a antagonist project targeting Benign Prostatic Hyperplasia (BPH); alpha 1 and alpha 2 agonist projects for urinary incontinence, pain and glaucoma; novel NPY5 antagonists for treating obesity.

Senior Scientist, Medicinal Chemistry, Allergan, Inc., 1989-1990

  • Initiated and led the medicinal chemistry effort focusing on the discovery of novel alpha 2 agonists for the treatment of glaucoma.
  • Initiated the medicinal chemistry effort focusing on hypotensive lipids for the treatment of glaucoma.
  • Part of the project team that discovered LumiganTM, a novel prostaglandin that is marketed for the treatment of glaucoma.

Honors & Publications

  • Lawrence Livermore Labs Homeland Security Industry Advisory Group
  • Allergan Discovery Research Award
  • Sole or co-inventor of over 75 patents issued in the United States
  • Published over 45 peer-reviewed articles and book chapters.


  • Ph.D., Organic Chemistry, Texas A&M University
  • B.S., Chemistry, Stevens Institute of Technology
Save Resume #2283
to Contact Form?

You must first click "Yes" to save this resume

Submit Request

You have no Saved Resumes

Add resumes within our various Ares of Expertise by clicking "Add Resume(s)" below.

Add Resume(s)